Economic costs of diabetes in the U.S. In 2007 - PubMed (original) (raw)
Review
. 2008 Mar;31(3):596-615.
doi: 10.2337/dc08-9017.
- PMID: 18308683
- DOI: 10.2337/dc08-9017
Review
Economic costs of diabetes in the U.S. In 2007
American Diabetes Association. Diabetes Care. 2008 Mar.
Erratum in
- Diabetes Care. 2008 Jun;31(6):1271
Abstract
Objective: The prevalence of diabetes continues to grow, with the number of people in the U.S. with diagnosed diabetes now reaching 17.5 million. The objectives of this study are to quantify the economic burden of diabetes caused by increased health resource use and lost productivity, and to provide a detailed breakdown of the costs attributed to diabetes.
Research design and methods: This study uses a prevalence-based approach that combines the demographics of the population in 2007 with diabetes prevalence rates and other epidemiological data, health care costs, and economic data into a Cost of Diabetes Model. Health resource use and associated medical costs are analyzed by age, sex, type of medical condition, and health resource category. Data sources include national surveys and claims databases, as well as a proprietary database that contains annual medical claims for 16.3 million people in 2006.
Results: The total estimated cost of diabetes in 2007 is 174billion,including174 billion, including 174billion,including116 billion in excess medical expenditures and 58billioninreducednationalproductivity.Medicalcostsattributedtodiabetesinclude58 billion in reduced national productivity. Medical costs attributed to diabetes include 58billioninreducednationalproductivity.Medicalcostsattributedtodiabetesinclude27 billion for care to directly treat diabetes, 58billiontotreattheportionofdiabetes−relatedchroniccomplicationsthatareattributedtodiabetes,and58 billion to treat the portion of diabetes-related chronic complications that are attributed to diabetes, and 58billiontotreattheportionofdiabetes−relatedchroniccomplicationsthatareattributedtodiabetes,and31 billon in excess general medical costs. The largest components of medical expenditures attributed to diabetes are hospital inpatient care (50% of total cost), diabetes medication and supplies (12%), retail prescriptions to treat complications of diabetes (11%), and physician office visits (9%). People with diagnosed diabetes incur average expenditures of 11,744peryear,ofwhich11,744 per year, of which 11,744peryear,ofwhich6,649 is attributed to diabetes. People with diagnosed diabetes, on average, have medical expenditures that are approximately 2.3 times higher than what expenditures would be in the absence of diabetes. For the cost categories analyzed, approximately 1in1 in 1in5 health care dollars in the U.S. is spent caring for someone with diagnosed diabetes, while approximately 1in1 in 1in10 health care dollars is attributed to diabetes. Indirect costs include increased absenteeism ($2.6 billion) and reduced productivity while at work ($20.0 billion) for the employed population, reduced productivity for those not in the labor force ($0.8 billion), unemployment from disease-related disability ($7.9 billion), and lost productive capacity due to early mortality ($26.9 billion).
Conclusions: The actual national burden of diabetes is likely to exceed the $174 billion estimate because it omits the social cost of intangibles such as pain and suffering, care provided by nonpaid caregivers, excess medical costs associated with undiagnosed diabetes, and diabetes-attributed costs for health care expenditures categories omitted from this study. Omitted from this analysis are expenditure categories such as health care system administrative costs, over-the-counter medications, clinician training programs, and research and infrastructure development. The burden of diabetes is imposed on all sectors of society-higher insurance premiums paid by employees and employers, reduced earnings through productivity loss, and reduced overall quality of life for people with diabetes and their families and friends.
Comment in
- The economic imperative to conquer diabetes.
Fradkin J, Rodgers GP. Fradkin J, et al. Diabetes Care. 2008 Mar;31(3):624-5. doi: 10.2337/dc08-0088. Diabetes Care. 2008. PMID: 18308686 No abstract available.
Similar articles
- Economic costs of diabetes in the U.S. in 2012.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2013 Apr;36(4):1033-46. doi: 10.2337/dc12-2625. Epub 2013 Mar 6. Diabetes Care. 2013. PMID: 23468086 Free PMC article. - Economic Costs of Diabetes in the U.S. in 2017.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2018 May;41(5):917-928. doi: 10.2337/dci18-0007. Epub 2018 Mar 22. Diabetes Care. 2018. PMID: 29567642 Free PMC article. - The cost of diabetes in Latin America and the Caribbean.
Barceló A, Aedo C, Rajpathak S, Robles S. Barceló A, et al. Bull World Health Organ. 2003;81(1):19-27. Epub 2003 Mar 11. Bull World Health Organ. 2003. PMID: 12640472 Free PMC article. - Economic Costs of Diabetes in the U.S. in 2022.
Parker ED, Lin J, Mahoney T, Ume N, Yang G, Gabbay RA, ElSayed NA, Bannuru RR. Parker ED, et al. Diabetes Care. 2024 Jan 1;47(1):26-43. doi: 10.2337/dci23-0085. Diabetes Care. 2024. PMID: 37909353 Review. - The impact of diabetes mellitus on healthcare costs in Italy.
Giorda CB, Manicardi V, Diago Cabezudo J. Giorda CB, et al. Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):709-19. doi: 10.1586/erp.11.78. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 22098288 Review.
Cited by
- A narrative review of the measurement methods for biomechanical properties of plantar soft tissue in patients with diabetic foot.
Yang XG, Peng Z, Liu X, Liu XL, Lu S. Yang XG, et al. Front Endocrinol (Lausanne). 2024 Jul 29;15:1332032. doi: 10.3389/fendo.2024.1332032. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39135623 Free PMC article. Review. - Biological, phytochemical and molecular docking characteristics of Laurus nobilis L. fresh leaves essential oil from Palestine.
Jaradat N, Hawash M, Qaoud MT, Al-Maharik N, Qadi M, Hussein F, Issa L, Saleh A, Saleh L, Jadallah A. Jaradat N, et al. BMC Complement Med Ther. 2024 Jun 8;24(1):223. doi: 10.1186/s12906-024-04528-9. BMC Complement Med Ther. 2024. PMID: 38851735 Free PMC article. - Nationwide Effectiveness and Efficiency of the National Diabetes Prevention Policy Versus the Penny-per-Ounce Excise Tax Policy on Sugar-Sweetened Beverages.
Bandaru P, Nana Sede Mbakop R, Ronda VP, Gokturk S, Forlemu AN. Bandaru P, et al. Cureus. 2024 Mar 9;16(3):e55866. doi: 10.7759/cureus.55866. eCollection 2024 Mar. Cureus. 2024. PMID: 38595899 Free PMC article. Review. - Characterization and Investigation of Novel Benzodioxol Derivatives as Antidiabetic Agents: An In Vitro and In Vivo Study in an Animal Model.
Hawash M, Al-Smadi D, Kumar A, Olech B, Dominiak PM, Jaradat N, Antari S, Mohammed S, Nasasrh A, Abualhasan M, Musa A, Suboh S, Çapan İ, Qneibi M, Natsheh H. Hawash M, et al. Biomolecules. 2023 Oct 6;13(10):1486. doi: 10.3390/biom13101486. Biomolecules. 2023. PMID: 37892167 Free PMC article. - Effects of recipient education disparity on living donor kidney transplant outcomes across different ethnic groups: a retrospective study in the United States.
Huang S, Xia X, Lai W, Hao X, Wu Y, Lv K, Luo Z, Romão EA, Ciancio G, Lv C, Meng Q, Yu T, Yuan Q. Huang S, et al. Transl Androl Urol. 2023 Jul 31;12(7):1137-1154. doi: 10.21037/tau-23-288. Epub 2023 Jul 11. Transl Androl Urol. 2023. PMID: 37554528 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical